# A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)

> **NCT05245968** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 78 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Pimitespib
- **DRUG:** Imatinib
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT05245968
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245968, "A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05245968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*